NIMH Psychoactive Drug Screening Program

NIMH精神活性药物筛选计划的目的是提供新的合成化合物和天然产物的筛选，这些化合物和天然产物可能用作基础和临床研究的研究工具或探针，作为精神障碍的治疗药物，以及作为PET、SPECT和fMRI配体用于功能性脑成像。该程序主要用于筛选先前已被证明具有与NIMH相关的药理学、生化或行为活性的化合物，而不是用于大规模、随机筛选天然产物或组合文库。然而，有限的筛选也可以对活性未知的合成或天然产物化合物的小文库以及通过nih资助的HTS或化学计划生成的hit或lead化合物进行筛选。化合物将由研究界提供，主要是由nih支持的研究人员提供。预计承包商将持续不断地收到和筛选化合物，尽管请求的数量每个月将有所不同。

The purpose of the NIMH Psychoactive Drug Screening Program is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as PET, SPECT, and fMRI ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries. However, limited screening may also be conducted on small libraries of synthetic or natural product compounds of unknown activity and on hit or lead compounds generated through NIH-funded HTS or chemistry programs. Compounds will be provided by the research community, primarily NIH-supported investigators. It is anticipated that the Contractor will receive and screen compounds on a continuous and on-going basis, although the volume of requests will vary from month to month.